Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Closing Bell Overtime' to talk Airbnb and Roku earnings.

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Fears that DeepSeek may be moving AI workloads from Nvidia's GPUs to Application-Specific Integrated Circuits combined with possible delays in the Blackwell chip release have caused lags in Nvidia ...

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Nvidia shares gained Monday, leading other chip stocks higher in a boost to the tech sector as the major U.S. indexes looked ...